PRTA Prothena Corporation plc
USHealthcareAs of 2026-07-10 16:00
Why PRTA matters now
Prothena Corporation plc (PRTA) is a US stock in Healthcare. The latest InvestLog snapshot shows $9.24 with -4.15% on the session and $483.7M in market capitalization; recent performance reads 1-month -1.54% and YTD -6.49%.
The latest financial table shown here is Q1 2026, with revenue of $51.1M, net income of $32.7M, and EPS of $0.60. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -17.4%.
The latest indexable market news headline is "PRTA Stock Rises Nearly 11% in Six Months: What's Driving It?" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Hold with a median target of $19.00; recent insider activity includes SCULLY WILLIAM P filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.53
P/S
8.07
EV/EBITDA
-1.95
DCF Value
$3.52
FCF Yield
-17.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
46.8%
Operating Margin
-217.9%
Net Margin
-260.9%
ROE
-49.9%
ROA
-43.2%
ROIC
-39.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $51.1M | $32.7M | $0.60 |
| Q4 2025 | $21.0K | $-21.6M | $-0.40 |
| FY 2025 | $9.7M | $-244.1M | $-4.53 |
| Q3 2025 | $2.4M | $-36.5M | $-0.68 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$19.00
Target (Median)
$19.00
Target Range
$19.00 - $19.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-0.32
Established in 2012 and headquartered in Dublin, Ireland, Prothena Corporation plc functions as a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapeutic solutions for critical, life-threatening conditions, primarily within the United States. The company's pipeline features several key programs: Birtamimab, an investigational humanized antibody, is currently undergoing Phase III clinical trials for the treatment of AL amyloidosis. Prasinezumab, a humanized monoclonal antibody, is progressing through Phase IIb trials for Parkinson's disease. Prothena has also completed Phase I clinical trials for PRX004, indicated for Transthyretin amyloidosis, and is advancing PRX005 through Phase I for Alzheimer's disease. In its earlier-stage development, Prothena is exploring PRX012 for Alzheimer's disease, alongside a dual Aß-Tau vaccine designed for both the treatment and prevention of Alzheimer's disease. Prothena maintains strategic partnerships, including a comprehensive license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. for antibodies targeting alpha-synuclein. The company also collaborates with Bristol-Myers Squibb on antibody development.